<SEC-DOCUMENT>0000910329-25-000015.txt : 20250804
<SEC-HEADER>0000910329-25-000015.hdr.sgml : 20250804
<ACCEPTANCE-DATETIME>20250804160738
ACCESSION NUMBER:		0000910329-25-000015
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250804
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250804
DATE AS OF CHANGE:		20250804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDIFAST INC
		CENTRAL INDEX KEY:			0000910329
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS [2090]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				133714405
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31573
		FILM NUMBER:		251180293

	BUSINESS ADDRESS:	
		STREET 1:		100 INTERNATIONAL DRIVE
		STREET 2:		18TH FLOOR
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21202
		BUSINESS PHONE:		4105818042

	MAIL ADDRESS:	
		STREET 1:		100 INTERNATIONAL DRIVE
		STREET 2:		18TH FLOOR
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHRITE INC
		DATE OF NAME CHANGE:	19951120

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XX
		DATE OF NAME CHANGE:	19950619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	00
		DATE OF NAME CHANGE:	19950619
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>med-20250804.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ee65c710-3669-4bd0-9fc7-095411b954f4,g:17184343-e122-4624-ab4d-5217644363eb,d:063ee147aeaf4a2fad104fb3462270b4-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>med-20250804</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000910329</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="med-20250804.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-04</xbrli:startDate><xbrli:endDate>2025-08-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i063ee147aeaf4a2fad104fb3462270b4_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 4, 2025</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">MEDIFAST, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(State or other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">jurisdiction of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-31573</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">13-3714405</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">100 International Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Baltimore</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">21202</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">410</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">581-8042</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.629%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock, par value $0.001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">MED</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">New York Stock Exchange</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;General Instruction A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-18">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-19">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:96.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:324pt;text-align:right;text-indent:-324pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div id="i063ee147aeaf4a2fad104fb3462270b4_7"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On August 4, 2025, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the second quarter ended June 30, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1993, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div id="i063ee147aeaf4a2fad104fb3462270b4_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibits.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="medq22025earningsrelease.htm">M</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="medq22025earningsrelease.htm">edifast Announces Se</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="medq22025earningsrelease.htm">cond Quarter 2025 Financial Results </a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i063ee147aeaf4a2fad104fb3462270b4_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Signature</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">MEDIFAST, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James P. Maloney</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">James P. Maloney</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 4, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>medq22025earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id8ad44e81ad540678a0e1bb75f8375fc_1"></div><div style="min-height:82.08pt;width:100%"><div><img alt="image_3.jpg" src="image_3.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div><div><font><br></font></div></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:125%">Medifast Announces Second Quarter 2025 Financial Results </font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">August&#160;4, 2025</font></div><div style="margin-bottom:0.08pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">BALTIMORE &#8211; (</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">BUSINESS WIRE</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">)--</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Medifast</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (NYSE&#58; MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution,&#160;</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">OPTA</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">VIA&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, today reported results for the second quarter ended June&#160;30, 2025.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Second Quarter 2025</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">Revenue&#58; $105.6 million, with revenue per active earning coach of $4,630</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">Active Coaches&#58; Independent active earning</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%"> OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA coaches of 22,800</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">Net Income&#58; $2.5 million or $0.22 per diluted share, which includes a gain on investment in LifeMD (Nasdaq&#58; LFMD) common stock of $2.0 million (net of tax)</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">Strong Balance Sheet&#58; $162.7 million in cash, cash equivalents, and investment securities with no debt</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;We are working diligently to transform our business as we look to help more people achieve optimal metabolic health,&#8221; said Dan Chard, CEO of Medifast. &#8220;We&#8217;re focused on new and impactful ways to reignite coach growth and productivity through targeted initiatives that aim to enhance our offering, expand tailored client solutions, and strengthen coach success, all while maintaining a disciplined balance sheet.&#8221;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Chard added, &#8220;Science will continue to guide our strategy and innovation. With 9 out of 10 U.S. adults metabolically unhealthy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">1,2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, recent analysis of data from a clinical study we commissioned led our scientists to discover that people who follow the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA 5 &#38; 1 Plan preserve 98% of their lean mass</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, a benefit that goes beyond weight loss. Preserving lean mass is a critical component of metabolic health. Building on this momentum, we will continue to leverage scientific findings from our team of experts to strengthen our core offering and unlock new areas of growth, including an upcoming scientific advancement that we believe will further solidify </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA&#8217;s role in helping people combat and reverse the effects of metabolic dysfunction.&#8221;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Second Quarter 2025 Results</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Second quarter 2025 revenue decreased 37.4% to $105.6 million from $168.6 million for the second quarter of 2024 primarily driven by a decrease in the number of active earning </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA coaches. The total number of active earning </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA coaches decreased 32.7% to 22,800 compared to 33,900 for the second quarter of 2024. The number of active earning </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA coaches has been trending downward year-over-year since the first quarter of 2023, driven by continued challenges with client acquisition. The average revenue per active earning </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA coach was $4,630, compared to $4,972 for the second quarter last year, primarily driven by continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss.</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:112%">O'Hearn M, et al. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. J Am Coll Cardiol. 2022&#59;80(2)&#58;138-151. doi&#58; 10.1016&#47;j.jacc.2022.04.046.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:112%">Nichols GA, et al. Cardiometabolic Risk Factors Among 1.3 Million Adults With Overweight or Obesity, but Not Diabetes, in 10 Geographically Diverse Regions of the United States, 2012&#8211;2013. Prev Chronic Dis 2017&#59;14&#58;160438. doi&#58; http&#58;&#47;&#47;dx.doi.org&#47;10.5888&#47;pcd14.160438.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:112%">Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obes Sci Pract. 2018&#59;5(1)&#58;3-14. doi&#58; 10.1002&#47;osp4.312. In a clinical study, individuals on the OPTAVIA 5&#38;1 Plan, retained 98% of lean mass at 16 weeks.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.08pt;width:100%"><div><img alt="image_3.jpg" src="image_3.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Gross profit decreased 37.9% to $76.6 million from $123.4 million for the second quarter of 2024. The decrease in gross profi</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">t was primarily </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">due to lower revenue. Gross profit margin was 72.6% compared to 73.2% in the second quarter of 2024.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Selling, general, and administrative expenses (&#8220;SG&#38;A&#8221;) decreased 40.8% to $77.7 million compared to $131.3 million for the second quarter of 2024. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">decrease</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> in SG&#38;A was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">primarily due to a $24.3 million decrease in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA coach compensation as a result of fewer active earning coaches and lower volumes. Additionally, the company incurred costs in the second quarter of 2024 that did not recur in the second quarter of 2025, including $12.5 million for supply chain optimization, $3.0 million for cancellation of the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA convention in future years, and $2.0 million for the company's collaboration with LifeMD. As a percentage of revenue, SG&#38;A decreased 430</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> basis points </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">year-over-year to 73.6% of revenue, as compared to 77.9% for the second quarter of 2024. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">decrease</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> in SG&#38;A as a percentage of revenue was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">primarily due to approximately 740 basis points for supply chain optimization initiatives and 180 basis points for cancellation of the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA convention incurred in the second quarter of 2024 that did not recur in the second quarter of 2025, partially offset by 440 basis points attributable to the loss of leverage on fixed costs to due to lower sales volumes.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The company's loss from operations for the period was $1.1 million, an improvement of 86.5% from $7.9 million in the prior year comparable period. As a percentage of revenue, loss from operations was 1.0% for the second quarter of 2025 compared to 4.7% in the prior-year period.</font></div><div style="margin-bottom:0.08pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Other income increased $6.7 million to $3.9 million compared to other expenses of $2.8 million for the second quarter of 2024. The increase in other income was primarily due to a gain on the company's investment in LifeMD common stock. The company's gain on investment in LifeMD common stock for the second quarter of 2025 was $2.6 million, compared to a loss on investment of $4.2 million for the corresponding period in 2024. The company sold its investment in LifeMD during the current quarter. However, the collaboration between LifeMD and the company continues and remains unchanged.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The effective tax rate was 13.7% for the second quarter of 2025 compared to 23.4% in the prior-year period. The change in the effective tax rate for the three months ended June&#160;30, 2025 was primarily driven by the increase in the limitation for executive compensation, which was magnified by the near break-even pre-tax position in the current year.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the second quarter of 2025, the company's net income was $2.5 million, or $0.22 per diluted share, based on approximately 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> million shares </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">of common stock outstanding. In the second quarter of 2024, net loss was $8.2 million, or $0.75 per diluted share, based on approximately 10.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> million shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> of common stock outstanding.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Capital Allocation and Balance Sheet</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The company&#8217;s balance sheet remains strong with $162.7 million in cash, cash equivalents and investment securities and no debt as of June&#160;30, 2025, compared to $162.3 million in cash, cash equivalents and investment securities and no debt at December&#160;31, 2024.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Outlook</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The company expects third quarter 2025 revenue to be in the range of $70 million to $90 million and third quarter 2025 diluted income&#47;(loss) per share to be in the range of ($0.60) to $0.00.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Conference Call Information</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The conference call is scheduled for today, Monday, August 4, 2025 at 4&#58;30 p.m. ET. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast&#8217;s website at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">www.MedifastInc.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.08pt;width:100%"><div><img alt="image_3.jpg" src="image_3.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">or directly at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">https&#58;&#47;&#47;viavid.webcasts.com&#47;starthere.jsp&#63;ei&#61;1726298&#38;tp_key&#61;605c001a0f</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> and will be archived online and available through November 3, 2025. In addition, listeners may dial (201) 389-0879 to join via telephone.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">A telephonic playback will be available from 8&#58;30 p.m. ET, August 4, 2025, through August 11, 2025. Participants can dial (412) 317-6671 and enter passcode 13754642 to hear the playback.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">About&#160;Medifast</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:700;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#58;</font><font style="background-color:#ffffff;color:#504640;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline"><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Medifast (NYSE&#58; MED) is the health and wellness company known for its habit-based and coach-guided lifestyle solution </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA&#174;, which provides people with a simple yet comprehensive approach to address obesity and support a healthy lifestyle. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA's holistic solution includes lifestyle plans with clinically proven health benefits, scientifically developed products, and a framework for habit creation &#8211; all reinforced by independent coach support for clients on their weight loss journeys. Through its collaboration with national virtual primary care provider LifeMD&#174; (Nasdaq&#58; LFMD) and its affiliated medical group, the holistic solution now includes access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature&#8482;. Visit the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA and Medifast websites for more information and follow &#64;Medifast on X and LinkedIn.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">MED-F</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Forward Looking Statements</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Please Note&#58; This release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;expect&#8221; or other similar words or the negative of such terminology. Similarly, descriptions of Medifast&#8217;s objectives, strategies, plans, goals, outlook or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of the management of Medifast and are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Medifast's inability to maintain and grow the network of independent </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA coaches&#59; Industry competition and new weight loss products, including weight loss medications, or services&#59; Medifast&#8217;s health or advertising related claims by </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA clients&#59; Medifast's inability to continue to develop new products&#59; effectiveness of Medifast's advertising and marketing programs, including use of social media by </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA coaches&#59; the departure of one or more key personnel&#59; Medifast's inability to protect against online security risks and cyberattacks&#59; risks associated with Medifast's direct-to-consumer business model&#59; disruptions in Medifast's supply chain&#59; product liability claims&#59; Medifast's planned growth into domestic markets including through its collaboration with LifeMD, Inc.&#59; adverse publicity associated with Medifast's products&#59; the impact of existing and future laws and regulations on Medifast&#8217;s business&#59; fluctuations of Medifast's common stock market price&#59; increases in litigation&#59; actions of activist investors&#59; the consequences of other geopolitical events, overall economic and market conditions and the resulting impact on consumer sentiment and spending patterns&#59; and Medifast's ability to prevent or detect a failure of internal control over financial reporting. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other filings filed with the United States Securities and Exchange Commission, including its quarterly reports on Form 10-Q and current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Investor Contact&#58;</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.08pt;width:100%"><div><img alt="image_3.jpg" src="image_3.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Medifast, Inc.</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Steven Zenker</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">InvestorRelations&#64;medifastinc.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(443) 379-5256</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.08pt;width:100%"><div><img alt="image_3.jpg" src="image_3.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollars in thousands, except per share amounts &#38; dividend data)</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.994%"><tr><td style="width:1.0%"></td><td style="width:41.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Six months ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Revenue</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">105,555</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">168,558</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">221,283</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">343,297</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cost of sales</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">28,911</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">45,120</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">60,395</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">92,567</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Gross profit</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">76,644</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">123,438</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">160,888</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">250,730</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Selling, general, and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">77,710</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">131,314</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">163,217</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">250,666</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Income (loss) from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(1,066)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(7,876)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(2,329)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">64</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other income (expense)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,369</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,296</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,671</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,519</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other income (expense)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,572</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(4,070)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3,059</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1,647)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3,941</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(2,774)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,730</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">872</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Income (loss) before provision for income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2,875</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(10,650)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">3,401</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">936</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Provision (benefit) for income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">395</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(2,496)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,693</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">773</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Net income (loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2,480</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(8,154)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">1,708</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">163</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Earnings (loss) per share - basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.23</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.75)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.16</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.01</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Earnings (loss) per share - diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.22</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.75)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.15</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.01</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Weighted average shares outstanding</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Basic</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,991</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,937</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,970</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,923</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">11,060</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,937</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">11,045</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,967</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.08pt;width:100%"><div><img alt="image_3.jpg" src="image_3.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollars in thousands, except par value)</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.546%"><tr><td style="width:1.0%"></td><td style="width:58.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br>2024</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Current Assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101,694</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:-1.19pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">90,928</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inventories, net</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">30,201</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">42,421</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Investments</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">60,979</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">71,416</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Income taxes, prepaid</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,513</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">9,054</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">9,639</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">206,441</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">214,404</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net of accumulated depreciation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">34,597</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">37,527</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">8,856</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">11,155</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">7,979</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">9,667</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deferred tax assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">11,460</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">11,460</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">TOTAL ASSETS</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">269,333</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:-1.19pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">284,213</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS' EQUITY</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Current Liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable and accrued expenses</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">40,260</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:-1.19pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">56,494</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Income taxes payable</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,485</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Current lease obligations</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,924</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,182</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">46,184</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">64,161</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Lease obligations, net of current lease obligations</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">7,144</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">9,943</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">53,328</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">74,104</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Stockholders' Equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock, par value $.001 per share&#58; 20,000 shares authorized&#59;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,991 and 10,938 issued and outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">at June 30, 2025 and December 31, 2024, respectively</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">11</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">11</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">37,323</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">33,136</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">179</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">180</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Retained earnings</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">178,492</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">176,782</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">216,005</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">210,109</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt;text-indent:-1.19pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</font></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">269,333</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">284,213</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>med-20250804.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ee65c710-3669-4bd0-9fc7-095411b954f4,g:17184343-e122-4624-ab4d-5217644363eb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:med="http://www.medifast1.com/20250804" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.medifast1.com/20250804">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="med-20250804_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="med-20250804_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.medifast1.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>med-20250804_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ee65c710-3669-4bd0-9fc7-095411b954f4,g:17184343-e122-4624-ab4d-5217644363eb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_c27c61a0-e824-4665-9f1b-92dc6a31ed3f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c7d2fec7-c81f-4c63-ac18-c584eca7a068_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_85689284-5def-4b9c-be01-feb38feabc06_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a15ee870-9b4f-459a-8706-063e011719ff_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_02f63a37-2a16-4574-a193-c9d6bf7e819f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_46e30ccf-3151-449a-999d-510ae63cea06_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5d4ce6cf-94e0-414d-a169-7524e89ceed5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f479e18d-2641-4cdc-ae64-a301b06d2855_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_60e82bfc-a137-4e84-87d3-e4fc213ab642_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_38f8bff6-455d-4e6e-b583-820deb75ed0e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_645b8d01-adb4-4425-be1d-7c220ceab704_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d09bd63b-a6ab-4535-9ef0-09a5b0d2c9e0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4e836e64-44d5-442d-9ec2-4afa3541711d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dd103446-2dff-4e9f-b90b-4250c8ee6e87_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_157ecad6-a0f0-470b-88ce-b159a7dfdf1b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ab57be40-3199-47fd-b387-b3ad7c013873_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cdf6d6c1-0cc4-47da-b44c-86cf20c3c739_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4505a983-910b-4672-b75a-0afdcf6eb687_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5fa9ac25-f407-4005-a24d-6fd950f1c736_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3b566e4a-d87d-42c7-a7ac-04c26aa8ecb2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d9c78503-e107-4ed9-a6cf-dc1a228defba_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bc98526a-1f7b-450f-810f-59ebc875ca58_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>med-20250804_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ee65c710-3669-4bd0-9fc7-095411b954f4,g:17184343-e122-4624-ab4d-5217644363eb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medifast1.com/role/Cover" xlink:type="simple" xlink:href="med-20250804.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a90c4ff5-ea36-4aa1-95ec-0d8656d825dc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_DocumentType_a90c4ff5-ea36-4aa1-95ec-0d8656d825dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_62b38aef-27ea-4397-b4e9-5023e84757ec" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_DocumentPeriodEndDate_62b38aef-27ea-4397-b4e9-5023e84757ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bd3fca5f-e85a-46ff-9966-a105abdf79e4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityRegistrantName_bd3fca5f-e85a-46ff-9966-a105abdf79e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8b991d47-32d0-4cdb-b283-b8b63e561938" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityAddressAddressLine1_8b991d47-32d0-4cdb-b283-b8b63e561938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_36bbd106-b25d-4a51-b3dc-18e947f413be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityAddressCityOrTown_36bbd106-b25d-4a51-b3dc-18e947f413be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_66ad36cd-a083-4797-9eb8-24d6bb3280d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityAddressStateOrProvince_66ad36cd-a083-4797-9eb8-24d6bb3280d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_889daeb8-bb29-4b22-810a-884da0c183e2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityAddressPostalZipCode_889daeb8-bb29-4b22-810a-884da0c183e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_38e77494-904f-4546-9039-5b84f8aa476e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_CityAreaCode_38e77494-904f-4546-9039-5b84f8aa476e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9c2c4ed5-bc72-4381-b59c-644298ad863d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_LocalPhoneNumber_9c2c4ed5-bc72-4381-b59c-644298ad863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_253daac3-ae5a-43fc-80da-49c963a4f51c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_Security12bTitle_253daac3-ae5a-43fc-80da-49c963a4f51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1fbd302c-70cf-41f3-97a2-f6182e89f76f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_TradingSymbol_1fbd302c-70cf-41f3-97a2-f6182e89f76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e41a6d94-aba8-4d8d-840e-10ca5819af01" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_SecurityExchangeName_e41a6d94-aba8-4d8d-840e-10ca5819af01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5421fec4-d198-4d77-b433-4c6df439cd6d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_WrittenCommunications_5421fec4-d198-4d77-b433-4c6df439cd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b956d21e-c707-4981-b682-315ddf80c45f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_SolicitingMaterial_b956d21e-c707-4981-b682-315ddf80c45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7151d510-a336-43ec-b978-02da38404edd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_PreCommencementTenderOffer_7151d510-a336-43ec-b978-02da38404edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f7f13cde-2f95-4991-9bd1-e46450b599de" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f7f13cde-2f95-4991-9bd1-e46450b599de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_19e8df37-beb4-4baf-84fb-79b86b6144f5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityEmergingGrowthCompany_19e8df37-beb4-4baf-84fb-79b86b6144f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e86e6f63-895c-4c6c-922a-bb96b14a9a0e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityCentralIndexKey_e86e6f63-895c-4c6c-922a-bb96b14a9a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_961e06f7-c59e-440d-b1d1-6173fcf2965e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_AmendmentFlag_961e06f7-c59e-440d-b1d1-6173fcf2965e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fbe8de20-75ec-4472-8dfc-2c0216181d7a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityTaxIdentificationNumber_fbe8de20-75ec-4472-8dfc-2c0216181d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c53d6c79-15c4-4c35-875f-8b5302525894" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityFileNumber_c53d6c79-15c4-4c35-875f-8b5302525894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1bf2c5c1-d607-472d-b320-50d0d1c5ca06" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_329f9469-dea8-4ebf-99c0-df00cf173c7c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1bf2c5c1-d607-472d-b320-50d0d1c5ca06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_3.jpg
<TEXT>
begin 644 image_3.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MH\^6.A%V::/J[-<E\1/B)HGPK\*W7B+Q)>"PTNV*AI-I9F9C@*J@$DDGH/Y
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M7P;_ &=? GC3P_/I=W\/]-L3)J.E31#SY&>]D#'.W<!AUP58 <D@XY^F+CX
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M9;BGVJPN$FC##&1N4D9&1D9[US<GQ^^&L+,K^/O#*LI(*G6+<$$=1]^OG/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEDIFAST, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 International Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baltimore<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">581-8042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000910329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3714405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="med-20250804.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="med-20250804.htm">med-20250804.htm</File>
    <File>med-20250804.xsd</File>
    <File>med-20250804_lab.xml</File>
    <File>med-20250804_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "med-20250804.htm": {
   "nsprefix": "med",
   "nsuri": "http://www.medifast1.com/20250804",
   "dts": {
    "inline": {
     "local": [
      "med-20250804.htm"
     ]
    },
    "schema": {
     "local": [
      "med-20250804.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "med-20250804_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "med-20250804_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.medifast1.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "med-20250804.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "med-20250804.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000910329-25-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000910329-25-000015-xbrl.zip
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M64X!PLB4]%B X2=Q/)(*XE0/PD.21OLL]EN 6D!U+KCDT&!G$@P@Q&+D/)!
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M7MOQ0U,EWK<R=%WWAZF_@JEWLRQGXED&W_AA\&L,WF.F?Q!L9_!%W34&O[=
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ML^MNI"H?*ID+N=Y;MD)[F7AWHI[-A<SFE\4BXUFEVN(?*J,RHXLY]R-.$(5
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M#R3# 1/)DB V<YPDS0P'8U.FTZC8/X(;%O@9-QE?3MY,_O3O;L+:51?0MT-
M,J>C[398.A:BB<1("H31X)1AUB7*)OGC/T0=IH$9-QE'4_G*4O@=G6^A.JXW
MFZNJN-N;VN9*<I8@2!*9[0:0=4U2@65-T#%)84/4XY8 S\(.$\.,VXSCR7SM
MQ%"712A:3&J_8'7;%*[,O54Z<@8D9#3#*:Q;RVC3[3:J&).A0:IQ<\)3S&$Z
MF'%K<22-KRR"LP8Z!4,5H-]"ZW9?FP\)_<@SIEA4C!(GNITT 8%XFQE">70"
M4QPN>L?EA6]C#Q/%C%N+$]$Z+W&<;+=7T#P<2\H2$R$"X<DJ%+IEQ/K("$@M
M%<4RR,9Q/8-_\F"84&;<9IR4XEFT&M]MH+G ;/C?IKYNUSBX2U?=YLR"B4G@
M; A>$NE=PE52\B2SWFBOF<1":8)>X[/@PT0R^V[C>&)GH8]CI*QQY0E*_.9G
MN,W!:-!)"V*L"MTZ*1#+N2/>6^V9=-;1*7:OOH(=IHD9=R#'D_G*:CC"?!>[
MG/>^=!>YU0RH3AD)R@*1DD;B&:8YC0RDD+C5:IP*'L$-B_Z,NY O)V\6.>#<
MW9Q$]+Y(]X73?2\U>4QFP"G)NE>VI,PXP>06" ^4,\T,BYF;(!=\ W[8.U S
M;DY.1^XL5/*^*'=-]J!$U"&SA"FLK640BIA,X53GE<#X<F7L%"]"?4$<IH49
M]RM'43B+\)]4H6XNZZ9GO=^!/ZZO<+J[[3?=F$\\J,!(U%V-G7',>0+%K6BD
MD>$51_4$BOB_3@P3R8P;FE,3/9ENWJZ>4'J*)P[?W%_H/KKWX0_?_ ]02P,$
M%     @ \H $6_'<#BM/(P  $GX! !P   !M961Q,C(P,C5E87)N:6YG<W)E
M;&5A<V4N:'1M[3UK<^)(DM_O5]1US\,=(31Z\;)[.X*QW3/>==N]C7OG[KYL
M%%(!-182HX=M]M=?9E4)! 8:,&X$:&*B;8-4CWQG5F;6^WXR\#^\[S/J??BO
M]_]=J9"+T$T'+$B(&S&:,(^D,0]ZY ^/Q?>D4E%/G8?#4<1[_818AE4E?X31
M/7^@\ON$)S[[D(WS_A?Y]_M?Q"3O.Z$W^O#>XP^$>W][P[T&]1R'-4SJ51VC
M5F]0@YF=3KW:;=CPC_MO\PV\"H_+=^)DY+._O1GPH-)G./]IP]*-QC Y>^1>
MTC\U#>/'-^+1#^_YH$>HG\ D ]IC_[;U/X>]-R2.W-E/Y)AJ/,<>/IT-:-2#
M*3IADH2#TRH,_\"BA+O4KU"?]X+3A#TEZNML9JLZ?,JO]</[;A@DL.$(/I2_
MRN^>[48,)L=U 6(L.A.?\,"#OT[MVC!Y(P?+7G!#/XQ.WQKBOS/\IM*E ^Z/
M3G\^AW$Z$?]9BVD05V(6\:Y\(.;_8:<FC"7_?)2[K</[/@]8!DW8!<#O$_-X
ME\8):05!F 8NBTF;N6'@D7^F-((%2JQ_Y $-7$Y]\H7%J9_$9'JC>81- 13Q
M]6S3;Q8";-5Q_DSCA'='6P.6.0,L9RZP6FD/YOWIK5DSSAQ-0&;%Y1N2<G>^
M@U];UW=7GVZ_7)*?WC8LTSPC)]D.YBVC6K-=\S66\;5]=7/9;I,_KKY<+EO
M:\'A7:6RBWUGW+:++9.3F_]M7_[TMMHX(Y\N+]YI).DS I+:3_J$ L,_,M\/
M6!P3-QP,:3 B]T'X&)!N&!$.#-^G'0Z"D,:@*/!Q-Z1NO])+N0<?^+S+Q#Y(
M'/IIPL- DVSRNE">)],DDWD@Q"**"SE-0;A&^-2;#[>?[UK?'^_+5O2OJQ8
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MURA#^$["[.#&/;2\M_E4UTY"][X?^L!&\<_D\J^4)Z-=<W5I&;XP_!,.!F$
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M!@  $               @ %=#P  ;65D+3(P,C4P.# T+GAS9%!+ 0(4 Q0
M   ( /* !%O9;(OK_ D  'U4   4              "  >T1  !M960M,C R
M-3 X,#1?;&%B+GAM;%!+ 0(4 Q0    ( /* !%M^](C!J@8  -\P   4
M          "  1L<  !M960M,C R-3 X,#1?<')E+GAM;%!+ 0(4 Q0    (
M /* !%OQW XK3R,  !)^ 0 <              "  ?<B  !M961Q,C(P,C5E
H87)N:6YG<W)E;&5A<V4N:'1M4$L%!@     %  4 2@$  (!&      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>med-20250804_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="med-20250804.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000910329</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-08-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">MEDIFAST, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-31573</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">13-3714405</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">100 International Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Baltimore</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">21202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">581-8042</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">MED</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NYSE</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
